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Isoform-selective inhibitora b s t r a c t
We investigated the inhibitory activity of sulfonamides incorporating adamantyl moieties against the
physiologically relevant human (h) CA (EC 4.2.1.1) isoforms hCA I, II III (cytosolic), IX and XII (transmem-
brane, tumor-associated). The presence of a benzenesulfonamide instead of an 1,3,4-thiadiazole-sulfon-
amide fragment in the molecule of CA inhibitors (CAIs) drastically affects both inhibition efficacy and
binding within the enzyme active site, as rationalized by means of X-ray crystallography of the adduct
of hCA II with 4-(1-adamantylcarboxamidomethyl)benzenesulfonamide. Comparing the present X-ray
structure with that of the corresponding 1,3,4-thiadiazole-sulfonamide compound possessing the 1-ada-
mantylcarboxamide moiety, important differences of binding emerged, which explain the highly differ-
ent inhibition profile of the two compounds against the investigated CA isoforms, most of which (CA I, II,
IX and XII) are important drug targets.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
In previous work from our laboratories1,2 we investigated the
drug design of carbonic anhydrase (CA, EC 4.2.1.1) inhibitors (CAIs)
incorporating the sulfonamide zinc-binding group (ZBG) and the
adamantyl moieties. The interest in such derivatives was due to
the fact that the adamantyl group induces an increased hydropho-
bicity to the compounds containing it, a property useful for target-
ing CA isoforms present in the brain,3 and which are inaccessible
by the more hydrophilic sulfonamides such as the clinically used
agent acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulfon-
amide) AZA.4–6 Furthemore, considering the wealth of structural
data available for CA–sulfonamide adducts,7,8 it appeared of inter-
est to investigate how this bulky moiety accommodates within the
enzyme active site, and how this influences biological activity.2 In-
deed, many sulfonamide CAIs incorporating both heterocyclic (e.g.,
1,3,4-thiadiazole-2-sulfonamide) and aromatic (mostly benzene-
sulfonamide) moieties, to which adamantyl-1-carboxamido- or
adamantyl-1-methylcarboxamido-groups have been attached,
were reported, of which compounds 1–4 are the most investigated
derivatives.1 Their interaction with the physiologically dominanthuman (h) cytosolic CA isoforms hCA I and II has been studied by
means of kinetic methods, and one such compound, the adaman-
tylcarboxamido analog of acetazolamide, compound 1, has also
been crystallized in adduct with hCA II, allowing us to understand
the interaction between the scaffold of this inhibitor and the active
site of the enzyme at molecular level.2
Sulfonamides and their isosteres (sulfamates, sulfamides, ure-
ates and hydroxamates) are pharmacologically relevant CAIs, with
applications as antiglaucoma, antiobesity, antiepileptic, antitumor
and diuretic drugs.3–8 Although X-ray crystal structures are avail-
able for the majority of the twelve catalytically active members
of the CA family (i.e., isozymes I-VA, IX, XII, XIII and XIV),9,10 most
of the reported complexes with inhibitors regard isozyme hCA II
(and to a less extent hCA I). These data are relevant for the drug de-
sign of isozyme-selective CAIs, and important such advances have
been made in the last years, mainly by rationalizing the various
sub-pockets for the binding of sulfonamide/sulfamide/sulfamate
inhibitors done by McKenna’s and our groups.6–9 In fact, the main
problem with the classical, clinically used sulfonamides is related
to the fact that they are promiscuous inhibitors of all (or most of
the) CA isozymes found in mammals.3 Thus, understanding at
molecular level the detailed interaction between the scaffold of
the inhibitor and the amino acid residues involved in its binding,
in each CA isoform, is crucial for obtaining isoform-selective CAIs.
Here we extend our previous investigation on adamantyl-contain-
ing sulfonamides, and report a crystallographic study of one such
compound (incorporating the benzenesulfonamide moiety) in
complex with hCA II. We also compare its binding with the adama-
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Molecular modeling has also been employed to investigate the
interaction of these inhibitors with isoforms more difficult to crys-
tallize, such as hCA I, III, IX and XII, some of which are important
drug targets.3,11,12 We were able to rationalize important differ-
ences in binding of the benzenesulfonamide versus the thiadia-
zole-sulfonamide derivatives incorporating such adamantyl
moieties.
2. Results and discussion
2.1. Chemistry
The adamantyl-containing aromatic/heterocyclic sulfoamides
1–4 have been reported earlier,1 being prepared by reaction of
the corresponding amino-sulfonamides with adamantyl-1-car-
boxyl chloride or adamantyl-1-methylcarboxyl chloride.
2.2. X-ray crystallography and docking studies
The structure of hCA II complexed with 4 has been determined
to 1.6 Å resolution (Table 1). Compound 4 is well ordered and re-
fined with full occupancy, with B factors that were comparable
to the solvent within the active site (Fig. 1A and Table 1). Similar
to other sulfonamide inhibitors bound to hCA II, the sulfonamide
amine nitrogen of 4 binds directly to the active site zinc ion along
with the side chains of His94, His96 and His119.6–9 The overall
Zn(N)4 coordination can be described as a distorted tetrahedron.
All other interactions between the sulfamoyl ZBG moiety and the
conserved residues Thr199/Glu106 are also preserved in this struc-
ture, as in the ones of CAs with other sulfonamide/sulfamate/sulf-
amide inhibitors (data not shown) investigated so far.6–9
Compared with the X-ray structure of the hCA II–1 derivative,2
sulfonamide 4 contains an extra CH2 group between the benzene-
sulfonamide and the adamantyl fragments of the molecule, which
confers a greater degree of flexibility to the tail and permits signif-
icant differences in the orientation of the bulky adamantyl moiety
when in complex with the enzyme. Thus, one of the salient fea-
tures of this complex was that whereas the adamantyl group in
the structure of hCA II–1 complex (PDB accession 3MHC)2 was lo-
cated between Phe131 and Ile91, the derivative 4 investigated hereTable 1
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c Rfree is calculated in the same manner as Rwork, except that it uses 5% of the reflectio
d Values in the parenthesis represents highest resolution bin.has the adamantyl group located between Phe131 and Val135
(Fig. 1A and B). In this way, inhibitor 4 favors binding of its ada-
mantyl tail to the common, hydrophobic pocket 1 of hCA II, which
is located towards Phe131 rather than pocket 2, reported earlier by
our groups and located between Phe131 and Ile91.13 Compound 4
forms a hydrogen bond with residue Gln92, but this bond is weaker
compared to the ones of the earlier reported adamantyl analog of
acetazolamide 1, which makes a hydrogen bond with this residue,
but also participates in a network of other hydrogen bonds involv-
ing residues Thr200, Pro201 and an ordered water molecule.2 The
buried surface area of 4, calculated by the program PISA14 is of
520 Å2 which is a relatively high value, due to the fact that the
adamantyl ring is placed in-between the hydrophobic pocket
(nearby Phe131) and Pro202 (Fig. 1A).
The present structure was superimposed to that of other CA iso-
forms in order to better understand the contribution of the ada-
mantyl tail to the isoform selectivity profile of these inhibitors.
Residue Gln92, involved in the binding of 4, is conserved in hCA
II,2 hCA I,15 hCA III,16 hCA IX12 and hCA XII,17 hence the hydrogen
bond between the oxygen atom of compound 4 and Gln92 will
likely remain same in all of these isoforms (Fig. 2). The presence
of this bulky side chain in the middle of the active site of hCA III
will prevent any similar sulfonamide derivative from binding effec-
tively to hCA III. Residue Phe131 of hCA II is replaced by the smaller
side chain Val131 in hCA IX and Ala131 in hCA XII, which probably
will allow the drug to sit into this pocket with a greater degree of
freedom. However Phe131 makes this pocket more hydrophobic,
hence this drug will be a better inhibitor for hCA II than the cancer
specific isoforms hCA IX and hCA XII. Another residue close to the
drug tail in the present structure is Val135, which is replaced by
less hydrophobic tails such as Ser135 in hCA XII and Ala 135 in
hCA I, hence this drug will most likely be a weaker inhibitor for
hCA XII and hCA I. In addition, Pro200 in hCA II, hCA IX and hCA
III is replaced by a bulky His200 in hCA I and a slightly shorter
Thr200 in hCA XII. The bulky His200 residue in proximity to the
inhibitor will make this drug a weaker inhibitor for hCA I compared
to the thiadiazole derivative 1 investigated earlier.2 Based on the
superposition of Figure 2, we predict that it is more likely that
hCA IX will be better inhibited by a shorter chain adamantyl analog
(as in compound 1) than the present drug 4, mainly due to the fact
that 1 binds to the selective pocket 2 instead of the common4ILX
1.54
P21















wed regions 0.0, 2.6, 97.4
16.0, 12.2, 15.8, 21.2, 29.0
n data omitted from refinement.
Figure 1. (A) Electron density of inhibitor 4 bound to hCA II with buried active site residues shown in sticks (stereo view). (B) Superposition of the present inhibitor 4 (green)
over previously reported adamantyl analog 1 (cyan).2 Active site residues in close proximity to the tail end of the inhibitor are indicated.
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predicted, based on the structure reported here (and the previous
one),2 that the adamantyl group which is highly hydrophobic in
nature, favor the binding of the inhibitors close to residues that
are also hydrophobic in nature, such as Phe131, Val135 and Ile91
(Figs. 1 and 2). However, the discrimination whether the inhibitor
will bind to the pocket 1 or 2, is dictated by the nature of the or-
ganic scaffold to which the sulfamoyl ZBG is attached, and by the
presence or absence of a linker between this scaffold and the ada-
mantyl moiety.
2.3. CA inhibition
In order to check whether our predictions, based on the X-ray
crystallography/docking studies presented above are true, we have
investigated inhibition of CA isoforms I, II, III, IX and XII with com-
pounds 1–4 (Table 2). It should be mentioned that originally,1 com-
pounds incorporating adamantyl moieties were investigated only
as hCA I and II inhibitors. In the previous crystallographic work,2
we have also investigated the inhibition of hCA IX and XII (antitu-
mor drug targets)6 with two such derivatives, the thiadiazole sul-
fonamides 1 and 2. Here we report the inhibition data of
compounds 1–4 with five CA isoforms, hCA I, II, III (cytosolic iso-
forms), IX and XII (transmembrane enzymes) (Table 2).18
As seen from data of Table 2, all the prediction we made based
on the crystallography/docking studies presented above, are in fact
true: compounds 3 and 4 incorporating a benzenesulfonamide in-
stead of a thiadiazole-sulfonamide scaffold present in 1 and 2,
were less effective CAIs against all investigated isoforms (probablydue to the interactions mentioned in the crystallography/docking
part of this study). However, several interesting facts emerged by
looking into detail at these data. Thus, whether for the cytosolic
isoforms hCA I, II, and III the benzenesulfonamides 3 and 4 were
several orders (1–2) of magnitude weaker CAIs compared to the
thiadiazole-sulfonamides 1 and 2, in the case of the transmem-
brane isoforms hCA IX and XII, there were only minor differences
of potency between the two types of derivatives. Thus, against
hCA IX 1 and 2 were effective inhibitors (KIs of 6.4–49.5 nM) but
almost the same type of inhibition profile was observed for 3 and
4 (KIs of 51.3–56.5 nM). The same situation (with even less differ-
ences of potency) was observed for the inhibition of hCA XII: deriv-
atives 1 and 2 were low nanomolar inhibitors (KIs of 2.8–4.7 nM)
but 3 and 4 also showed inhibition constants in the same range,
of 7.1–9.4 nM (Table 2). This inhibition profile outlined above ren-
der the benzenesulfonamides incorporating adamantyl moieties
(such as 3 and 4) isoform-selective inhibitors for the tumor-associ-
ated isoforms versus the cytosolic ones hCA I and II, a profile not
shared with the structurally-related 1,3,4-thiadiazole-sulfona-
mides (such as 1 and 2).
3. Conclusions
We investigated the inhibitory activity of sulfonamides incor-
porating adamantyl moieties against several physiologically rele-
vant isoforms, that is, hCA I, II III (cytosolic), IX and XII
(transmembrane, tumor-associated). The presence of a benzene-
sulfonamide instead of an 1,3,4-thiadiazole-sulfonamide fragment
in the molecule of such inhibitors drastically affects both inhibition
Figure 2. Overlay of hCAII with compound 4 (green), hCA II with earlier reported
adamantyl analog 1 (cyan), hCA IX (pink), hCA XII (yellow), hCA III (grey) and hCA I
(purple). Residues Q92, F131, V135 and L198 of hCAII are shown in sticks.
S. Biswas et al. / Bioorg. Med. Chem. 21 (2013) 2314–2318 2317efficacy and binding within the enzyme active site, as rationalized
by means of X-ray crystallography/docking studies of the adduct of
4-(1-adamantylcarboxamidomethyl)benzenesulfonamide with
these isoforms. Comparing the X-ray structure of this compound
bound to hCA II with that of the corresponding 1,3,4-thiadiazole-
sulfonamide compound possessing the 1-adamantylcarboxamide
moiety, important differences of binding emerged, which explain
the highly different inhibition profile of the two compounds
against the investigated CA isoforms, most of which (CA I, II, IX
and XII) are important drug targets. Indeed, the aromatic derivative
binds in the commonly utilized hydrophobic pocket within the hCA
II active site (between Phe131 and Val135), whereas the thiadia-
zole derivatives binds in the less utilized pocket (defined byTable 2
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a Errors in the range of ±10% of the reported data from three different assays by a sto
b From Ref. 1.
c From Ref. 2.
d This work.Phe131 and Ile91). This binding mode and the differences of amino
acid residues within these isoforms active sites, render the ben-
zenesulfonamide derivatives incorporating adamantyl groups CA
IX/XII-selective inhibitors.
4. Materials and methods
4.1. Chemistry
Compounds 1–4 were reported earlier by one of our groups.1
4.2. X-ray crystallography and structure determination
hCA II was purified to electrophoretic homogeneity according to
previously described protocol.2 For crystallization, the sulfonamide
4 was directly added to the well solution. The drug was initially
dissolved in 100% DMSO, and dilution with the crystallization buff-
fer was done till a final DMSO concentration 0.2% has been reached
in the drop. The crystallization drops were setup according to the
hanging drop vapor diffusion method by mixing 5 ll of precipitant
with 5 ll of protein.2 A protein to drug ratio of 1:2 was used for
this study. The protein concentration used in the drop was of
450 lM. The crystallization conditions were: 1.6 M sodium citrate,
50 mM Tris, pH 8.0. Crystals appeared within 48 h of incubation at
room temperature. In addition to co-crystallization, crystals were
also soaked in drug and immersed in precipitant solution contain-
ing 25% glycerol just before mounting it directly into liquid nitro-
gen stream for data collection. Dataset was collected using a
Rigaku RU H3R Cu rotating anode at 50 kV and 20 mA. The temper-
ature for data collection was 100 K and an R-AXIS IV++ image plate
system with Osmic Varimax Optics was used for recording images.
The crystal to detector distance was 80 mm with 1 oscillation and
5 min exposure per frame. Crystals diffracted to a resolution of
1.6 Å (Table 1). The images were processed using HKL2000.19
The structure was solved by molecular replacement using a
high resolution structure (2ILI) of hCA II as a starting model.20
The program PHASER in PHENIX21 was used to get the initial
phases. The ligand coordinates were generated using PRODRG22
and the restraints files using PHENIX eLBOW.21 Refinement was
carried out in PHENIX by setting aside 5% of reflections for Rfree cal-
culations. Iterative model building was performed in COOT23 until
a reasonable Rcryst was achieved. The validity of the model was





3: n = 0
4: n = 1
KI
a (nM)
hCA IIId hCA IX hCA XII
1.2  106 6.4c 2.8c
1.4  106 49.5c 4.7 c
>1.0  107 51.3d 7.1d
>1.0  107 56.5d 9.4d
2  105 b 25b 2.5b
pped-flow CO2 hydration method.19
2318 S. Biswas et al. / Bioorg. Med. Chem. 21 (2013) 2314–2318The data reduction statistics and refinement parameters are listed
in Table 1.
Superposition of this compound (4) over that of derivative 1
(PDB code 3MHC)2 bound gave a RMSD value of 0.116 Å, showing
strong similarity between these structures.
4.3. CA inhibition
An Applied Photophysics stopped-flow instrument has been
used for assaying the CA catalysed CO2 hydration activity. Phenol
red (at a concentration of 0.2 mM) has been used as indicator,
working at the absorbance maximum of 557 nm, with 20 mM
Hepes (pH 7.5 for the a-CAs) as buffer, and 20 mM Na2SO4 (for
maintaining constant the ionic strength), following the initial rates
of the CA-catalyzed CO2 hydration reaction for a period of 10–
100 s.18 The CO2 concentrations ranged from 1.7 to 17 mM for
the determination of the kinetic parameters and inhibition con-
stants. For each inhibitor at least six traces of the initial 5–10% of
the reaction have been used for determining the initial velocity.
The uncatalyzed rates were determined in the same manner and
subtracted from the total observed rates. Stock solutions of inhib-
itor (10 mM) were prepared in distilled–deionized water and dilu-
tions up to 0.01 lM were done thereafter with distilled–deionized
water. Inhibitor and enzyme solutions were preincubated together
for 15 min at room temperature prior to assay, in order to allow for
the formation of the E–I complex. The inhibition constants were
obtained by non-linear least-squares methods using PRISM 3, as
reported earlier,26 and represent the mean from at least three dif-
ferent determinations. Human CA isozymes were prepared in re-
combinant form as reported earlier by our groups.27,28,9
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